Aditxt Advances with Appili Shareholder Approval for Acquisition

Aditxt Inc., a company listed on NASDAQ under the ticker ADTX, has announced a strong step forward in its acquisition of Appili Therapeutics Inc. Shareholders of Appili have overwhelmingly voted in favor of the deal, which involves Aditxt acquiring all Class A common shares of Appili. This acquisition is a part of Aditxt’s broader strategy to enhance its health innovation portfolio, which focuses on bringing together research institutions, industry partners, and stakeholders to drive transformative health solutions. Aditxt operates programs centered on immune health and precision health, and has plans to launch additional programs targeting public health and women's health. The transaction's closing is contingent upon several conditions, such as shareholder approval and Aditxt securing sufficient funding. The announcement reflects Aditxt's continued commitment to advance its mission of addressing critical health challenges through innovative solutions.